Business Description
X4 Pharmaceuticals Inc
NAICS : 325412
SIC : 2836
ISIN : US0428731097
Compare
Compare
Traded in other countries / regions
XFOR.USA48Q.Germany IPO Date
2017-11-16Description
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.83 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 0.55 | |||||
| Debt-to-EBITDA | -0.29 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 31.6 | |||||
| 3-Year EPS without NRI Growth Rate | 31 | |||||
| 3-Year FCF Growth Rate | 33.8 | |||||
| 3-Year Book Growth Rate | -57.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.52 | |||||
| 9-Day RSI | 27.9 | |||||
| 14-Day RSI | 31.18 | |||||
| 6-1 Month Momentum % | 49.43 | |||||
| 12-1 Month Momentum % | -23.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.64 | |||||
| Quick Ratio | 6.64 | |||||
| Cash Ratio | 6.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -96.1 | |||||
| Shareholder Yield % | -86.46 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -228.66 | |||||
| ROA % | -100.66 | |||||
| ROIC % | -264.97 | |||||
| ROC (Joel Greenblatt) % | -1515.38 | |||||
| ROCE % | -118.17 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.24 | |||||
| Price-to-Tangible-Book | 2.97 | |||||
| EV-to-EBIT | -0.46 | |||||
| EV-to-EBITDA | -0.46 | |||||
| EV-to-Forward-Revenue | 5.05 | |||||
| EV-to-FCF | -0.85 | |||||
| Price-to-Net-Current-Asset-Value | 3.68 | |||||
| Price-to-Net-Cash | 4.18 | |||||
| Earnings Yield (Greenblatt) % | -217.39 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XFOR
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
X4 Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.04 | ||
| Beta | 0.57 | ||
| Volatility % | 100.03 | ||
| 14-Day RSI | 31.18 | ||
| 14-Day ATR ($) | 0.088161 | ||
| 20-Day SMA ($) | 1.13257 | ||
| 12-1 Month Momentum % | -23.98 | ||
| 52-Week Range ($) | 0.65 - 2.575 | ||
| Shares Outstanding (Mil) | 164.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
X4 Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
X4 Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
X4 Pharmaceuticals Inc Frequently Asked Questions
What is X4 Pharmaceuticals Inc(XFOR)'s stock price today?
The current price of XFOR is $0.92. The 52 week high of XFOR is $2.58 and 52 week low is $0.65.
When is next earnings date of X4 Pharmaceuticals Inc(XFOR)?
The next earnings date of X4 Pharmaceuticals Inc(XFOR) is 2023-11-03 Est..
Does X4 Pharmaceuticals Inc(XFOR) pay dividends? If so, how much?
X4 Pharmaceuticals Inc(XFOR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers